Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of subcutaneous amivantamab-based regimens in EGFR-mutated advanced or metastatic non-small cell lung cancer
MOH_2022-12-06_012218Phase 2Recruiting
- Sponsor
- GC Care
- Start
- Nov 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab, lazertinib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (7 arms), sponsored by GC Care. Started Nov 2022; status: recruiting.
02
Drugs
amivantamablazertinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-12-06_012218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-06_012218.